The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662 · cited 3×
“Treatment with GSK2879552 increased LSD1 signal enrichment at both SCLC specific typical and super enhancers (Figure 3J), as previously defined in NCI-H2171 cells (Hnisz et al., 2013).”
BackgroundResultA decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Active Genes Are Tri-Methylated at K4 of Histone H3
Santos-Rosa, H., Schneider, R., Bannister, A. J., Sherriff, J., Bernstein, B. E., Emre, N. C. T., Schreiber, S. L., Mellor, J., & Kouzarides, T. (2002) · Nature · doi:10.1038/nature01080 · Cited by 2,138
Rhodes, D. R., Kalyana-Sundaram, S., Mahavisno, V., Varambally, R., Yu, J., Briggs, B. B., Barrette, T. R., Anstet, M. J., Kincead-Beal, C., Kulkarni, P., et al. (2007) · Neoplasia · doi:10.1593/neo.07112 · Cited by 2,060
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Self-citationGenomic Maps and Comparative Analysis of Histone Modifications in Human and Mouse
Bernstein, B. E., Kamal, M., Lindblad-Toh, K., Bekiranov, S., Bailey, D. K., Huebert, D. J., McMahon, S., Karlsson, E. K., Kulbokas, E. J., Gingeras, T. R., et al. (2005) · Cell · doi:10.1016/j.cell.2005.01.001 · Cited by 1,527
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Peifer, M., Fernández-Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2396 · Cited by 1,397
MYC oncogenes and human neoplastic disease
Nesbit, C. E., Tersak, J. M., & Prochownik, E. V. (1999) · Oncogene · doi:10.1038/sj.onc.1202746 · Cited by 1,158
Rudin, C. M., Durinck, S., Stawiski, E. W., Poirier, J. T., Modrusan, Z., Shames, D. S., Bergbower, E. A., Guan, Y., Shin, J., Guillory, J., et al. (2012) · Nature Genetics · doi:10.1038/ng.2405 · Cited by 1,077
Cited by
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,570
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J.-P. J., & Baylin, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,128
Talele, T. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00472 · Cited by 1,023
Small-cell lung cancer: what we know, what we need to know and the path forward
Gazdar, A. F., Bunn, P. A., & Minna, J. D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.87 · Cited by 904
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
Sheng, W., LaFleur, M. W., Nguyen, T. H., Chen, S., Chakravarthy, A., Conway, J. R., Li, Y., Chen, H., Yang, H., Hsu, P.-H., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.052 · Cited by 693
Clinical epigenetics: seizing opportunities for translation
Berdasco, M., & Esteller, M. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0074-2 · Cited by 498
LSD1/KDM1A inhibitors in clinical trials: advances and prospects
Fang, Y., Liao, G., & Yu, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0811-9 · Cited by 438
Epigenetics in cancer stem cells
Toh, T. B., Lim, J. J., & Chow, E. K.-H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0596-9 · Cited by 422
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 413
Self-citationNfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility
Denny, S. K., Yang, D., Chuang, C.-H., Brady, J. J., Lim, J. S., Grüner, B. M., Chiou, S.-H., Schep, A. N., Baral, J., Hamard, C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.052 · Cited by 368
Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity
Wainwright, E. N., & Scaffidi, P. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.04.004 · Cited by 342
The timeline of epigenetic drug discovery: from reality to dreams
Ganesan, A., Arimondo, P. B., Rots, M. G., Jeronimo, C., & Berdasco, M. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0776-0 · Cited by 341
Targeting epigenetic regulators to overcome drug resistance in cancers
Wang, N., Ma, T., & Yu, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01341-7 · Cited by 311
Inhibitors of Protein Methyltransferases and Demethylases
Kaniskan, H. Ü., Martini, M. L., & Jin, J. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00801 · Cited by 297
Current status and perspectives of patient-derived xenograft models in cancer research
Lai, Y., Wei, X., Lin, S., Qin, L., Cheng, L., & Li, P. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0470-7 · Cited by 295
EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET
Goossens, S., Vandamme, N., Van Vlierberghe, P., & Berx, G. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.06.006 · Cited by 295
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
Current Diagnosis and Management of Small-Cell Lung Cancer
Wang, S., Zimmermann, S., Parikh, K., Mansfield, A. S., & Adjei, A. A. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.034 · Cited by 282
Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity
Skrypek, N., Goossens, S., De Smedt, E., Vandamme, N., & Berx, G. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.08.004 · Cited by 271
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence
Duy, C., Li, M., Teater, M., Meydan, C., Garrett-Bakelman, F. E., Lee, T. C., Chin, C. R., Durmaz, C., Kawabata, K. C., Dhimolea, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1375 · Cited by 253
Epigenetic programming, early life nutrition and the risk of metabolic disease
Block, T., & El-Osta, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.09.003 · Cited by 130
Inhibiting the coregulator CoREST impairs Foxp3+ Treg function and promotes antitumor immunity
Xiong, Y., Wang, L., Di Giorgio, E., Akimova, T., Beier, U. H., Han, R., Trevisanut, M., Kalin, J. H., Cole, P. A., & Hancock, W. W. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131375 · Cited by 72
Lin, Z., Wang, X., Bustin, K. A., Shishikura, K., McKnight, N. R., He, L., Suciu, R. M., Hu, K., Han, X., Ahmadi, M., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00616 · Cited by 43
Metadata
- Authors
- Mohammad, H. P., Smitheman, K. N., Kamat, C. D., Soong, D., Federowicz, K. E., Van Aller, G. S., Schneck, J. L., Carson, J. D., Liu, Y., Butticello, M., Bonnette, W. G., Gorman, S. A., Degenhardt, Y., Bai, Y., McCabe, M. T., Pappalardi, M. B., Kasparec, J., Tian, X., McNulty, K. C., Rouse, M., McDevitt, P., Ho, T., Crouthamel, M., Hart, T. K., Concha, N. O., McHugh, C. F., Miller, W. H., Dhanak, D., Tummino, P. J., Carpenter, C. L., Johnson, N. W., Hann, C. L., & Kruger, R. G.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 28
- Issue
- 1
- Pages
- 57-69
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1603797292
- Cited by
- 504
- References
- 45
- FWCI
- 21.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.